RxDoctor Payments Data

Stanley Sicher, MD

Nephrology · Pueblo, CONPI 1295733350

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 55 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$304
  • AstraZeneca$190
  • Otsuka America Pharmaceutical, Inc.$151
  • Amgen$128
  • Bayer$95
  • Mallinckrodt Hospital Products Inc.$93
  • plus $341 from 11 others

What the payments were for

  • Speaking & faculty fees$20015%
  • Food & beverage$1,10185%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 55th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$240,822
Medicare patients
229
Services billed
3,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lanthanum Carbonate32$28,428
Sevelamer Carbonate76$20,397
KerendiaFinerenone14$17,543
OzempicSemaglutide14$13,296
EliquisApixaban16$12,867
LokelmaSodium Zirconium Cyclosilicate20$8,727
Cinacalcet Hcl12$4,812
Calcium Acetate32$4,493
Tacrolimus30$1,521
Amlodipine Besylate138$924
Nifedipine ErNifedipine71$835
Omeprazole26$746
Carvedilol99$706
Gabapentin37$657
Losartan Potassium74$655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$95$17,54314 claims
AstraZenecaLokelma$190$8,72720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 152 nephrology providers in Colorado.

Other nephrology in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →